25 completed, 17 terminated, 14 recruiting, 8 active not recruiting. 71 Phase 1, 23 Phase 2, 1 Early Phase 1.
Follow Advanced or Metastatic Solid Tumors: new trials by email Literature Review of Advanced or Metastatic Solid Tumors trials Research Report on Advanced or Metastatic Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors KGX105 injection - Advanced or Metastatic Solid Tumors | Phase 1 | Not yet recruiting | Kangabio AUSTRALIA LTD PTY | 85 | 2026-08-01 | 2026-07-21 |
| A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors SHY-ONC6 - Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | SHY Therapeutics | 30 | 2026-06-24 | 2026-10-22 |
| PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors EB-PT-CAR-NK-S, EB-PT-CAR-NK-D, Lymphodepleting chemotherapy - Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 60 | 2026-03-02 | 2026-04-06 |
| A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors TAK-188 - Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Takeda | 273 | 2025-11-19 | 2026-10-14 |
| A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma WTX-330 - Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Werewolf Therapeutics, Inc. | 24 | 2025-04-21 | 2026-10-19 |
| A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors CHS-1000, Toripalimab - Advanced or Metastatic Solid Tumors | Phase 1 | Not yet recruiting | Coherus Oncology, Inc. | 48 | 2025-02-15 | 2024-09-19 |
| Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors IPH4502 - Advanced or Metastatic Solid Tumors | Phase 1 | Active not recruiting | Innate Pharma | 145 | 2025-01-24 | 2026-07-27 |
| A Phase 1 Study of LNCB74 in Advanced Solid Tumors LNCB74 - Ovarian Cancer, Breast Cancer | Phase 1 | Recruiting | LigaChem Biosciences, Inc. | 145 | 2025-01-07 | 2026-10-29 |
| Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors HM16390, pembrolizumab - Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | Hanmi Pharmaceutical Company Limited | 292 | 2024-12-11 | 2025-12-17 |
| A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients KGX101 injection, Envafolimab - Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | Kangabio AUSTRALIA LTD PTY | 57 | 2024-11-27 | 2026-04-24 |
| To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors DAY301 - Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | Day One Biopharmaceuticals, Inc. | 300 | 2024-11-18 | 2026-07-22 |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies ETX-19477 - Advanced or Metastatic Solid Tumors, Breast Cancer | Phase 1 / Phase 2 | Recruiting | 858 Therapeutics, Inc. | 120 | 2024-05-13 | 2026-03-27 |
| A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination PF-07329640, sasanlimab, bevacizumab - Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-05-09 | 2024-11-06 |
| A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors ONO-4538HSC - Advanced or Metastatic Solid Tumors | Phase 1 | Active not recruiting | Ono Pharmaceutical Co., Ltd. | 31 | 2024-05-07 | 2026-10-08 |
| A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors VIO-01 - Advanced or Metastatic Solid Tumors, Breast Cancer | Phase 1 / Phase 2 | Terminated | Valerio Therapeutics | 6 | 2024-01-10 | 2025-03-17 |
| A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors TGI-6 Injection - Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | Hefei TG ImmunoPharma Co., Ltd. | 123 | 2024-01-03 | 2024-04-18 |
| Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 PMC-309 monotherapy, PMC-309 Dose Escalation in Combination with Pembrolizumab(KEYTRUDA®), PMC-309 Dose Expansion - Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | PharmAbcine | 67 | 2024-01-03 | 2025-12-30 |
| Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors BH3120, pembrolizumab - Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | Hanmi Pharmaceutical Company Limited | 216 | 2023-12-28 | 2026-09-25 |
| This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors. KGX101- Cohort -1, KGX101- Cohort 1, KGX101- Cohort 2 - Advanced or Metastatic Solid Tumors | Phase 1 | Active not recruiting | Kangabio AUSTRALIA LTD PTY | 54 | 2023-12-13 | 2026-04-29 |
| Phase I of XKH002 Injection in Patients XKH002 Injection - Advanced or Metastatic Solid Tumors | Phase 1 | Unknown | Zhejiang Kanova Biopharmaceutical Co., LTD | 110 | 2023-11-27 | 2024-10-10 |
Showing 20 of 73. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (11) · Neoplasm Metastasis (11) · Neoplasms (11) · Colorectal Neoplasms (9) · Ovarian Neoplasms (9) · Breast Neoplasms (8) · Melanoma (8) · Prostatic Neoplasms (7) · Endometrial Neoplasms (6) · Stomach Neoplasms (6) · Carcinoma, Transitional Cell (4) · Squamous Cell Carcinoma of Head and Neck (4) · Colonic Neoplasms (3) · Lung Neoplasms (3) · Pancreatic Neoplasms (3)
Neoplasms by Site (25) · Neoplasms (23) · Skin and Connective Tissue Diseases (17) · Skin Diseases (16) · Digestive System Diseases (14) · Digestive System Neoplasms (14) · Neoplasms by Histologic Type (14) · Lung Diseases (13) · Respiratory Tract Diseases (13) · Respiratory Tract Neoplasms (13) · Thoracic Neoplasms (13) · Urogenital Diseases (13) · Urogenital Neoplasms (13) · Colonic Diseases (12) · Endocrine Gland Neoplasms (12)
pembrolizumab (13) · Albumin-Bound Paclitaxel (3) · Nivolumab (3) · envafolimab (3) · 130-nm albumin-bound paclitaxel (2) · Capecitabine (2) · Carboplatin (2) · Cisplatin (2) · Injections (2) · Pemetrexed (2) · trifluridine tipiracil drug combination (2) · Axitinib (1) · Azacitidine (1) · Bevacizumab (1) · Bortezomib (1)
NextCure, Inc. (5) · Erasca, Inc. (3) · Hanmi Pharmaceutical Company Limited (3) · Kangabio AUSTRALIA LTD PTY (3) · Merck Sharp & Dohme LLC (3) · Ono Pharmaceutical Co., Ltd. (3) · Akeso (2) · DynamiCure Biotechnology (2) · Pfizer (2) · Takeda (2) · Werewolf Therapeutics, Inc. (2) · 3D Medicines (Sichuan) Co., Ltd. (1) · 858 Therapeutics, Inc. (1) · ASLAN Pharmaceuticals (1) · Abbott (1)
United States (43) · China (15) · Australia (12) · Japan (9) · Canada (6) · South Korea (6) · France (4) · Spain (3) · United Kingdom (3) · Brazil (2) · Israel (2) · Switzerland (2) · Chile (1) · Croatia (1) · Denmark (1)
Han Myint, MD (3) · Project Leader (3) · Alex HL Wong, MMedSc (1) · Alexander Philipovskiy, M.D., PhD (1) · Andrea Tazbirkova, Dr (1) · Benjamin Thompson, MD, PhD (1) · Chaohe Wang (1) · Daniel McCormick (1) · Darrin Beaupre, MD,PhD (1) · Donald L Durden, MD, PhD (1) · Eric Chetaille, MD (1)
PMID 22921184, PMID 27269741, PMID 27733243, PMID 29094232, PMID 29489427, PMID 30110194, PMID 31100038, PMID 32308505, PMID 33433743, PMID 33783067, PMID 35226739, PMID 35932387, PMID 36082616, PMID 36331676, PMID 38982653, PMID 39779468, PMID 40373381, PMID 40618725, PMID 40713179, PMID 40957773
2023 (2), 2009 (1)